BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial ContrastDefense World · Oct 2, 2026
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Sees Large Increase in Short InterestDefense World · Sep 18, 2026
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva PharmaceuticalsGlobeNewsWire · Aug 28, 2026
Biopharma firm BioXcel Therapeutics files for bankruptcy in USReuters · Aug 27, 2026
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research · Aug 13, 2026
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Recommendation of “Hold” by BrokeragesDefense World · Aug 3, 2026BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.44 | -$0.49 | Miss |
| May 15, 2026 | -$0.59 | -$0.54 | Beat |
| Mar 26, 2026 | -$0.34 | -$0.58 | Miss |
| Nov 12, 2025 | -$1.54 | -$2.18 | Miss |
| Aug 12, 2025 | -$2.30 | -$2.45 | Miss |
| May 12, 2025 | -$2.72 | -$1.50 | Beat |